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6/j.bHaploidentical hematopoietic stem cell transplantation (HSCT) is a potentially curative therapeutic regimen
that could increase donor availability to nearly 100%. Rapid advances in medical technology and the applica-
tion of novel drugs mean that most haploidentical HSCT-associated complications can now be prevented or
remarkably well controlled, even cured. However, relapsing hematologic malignancy remains a major cause of
death in haploidentical HSCT recipients. Haploidentical HSCT should theoretically trigger a more potent
graft-versus-tumor effect compared with human leukocyte antigen-identical transplantation, due mainly to
the major histocompatibility complex and minor histocompatibility anitigen disparities on donors’ immune
cells and recipients’ tumor cells. The underlying mechanisms of such relapsing hematologic malignancies re-
main elusive. In this review, we suggest correlating factors and potential mechanisms and examine feasible
therapeutic and preventive strategies for relapsing hematologic malignancies after haploidentical HSCT.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) is a potentially curative strategy for hemato-
logic malignancies [1], solid malignancies [2], and
other nonmalignant diseases [3]. This regimen has
benefited patients since its emergence more than 50
years ago. In current clinical situations, a human leu-
kocyte antigen (HLA)-matched HSCT is commonly
the preferred type of transplantation, with HLA-
matched sibling donors usually the first choice. For
cases in which an HLA-matched related donor is not
available, an HLA-matched unrelated donor is identi-e Marrow Transplantation Center, First Affiliated
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bmt.2011.02.013fied and selected through a donor registry. Clinical
practice has demonstrated that only 50%-60% of
HSCTs from HLA-matched donors are successful,
with a much lower rate of success in patients of ethnic
minorities [4].With the aim of solving this conundrum
and benefiting more patients, much effort has been ex-
pended in searching for feasible alternative ap-
proaches. Haploidentical HSCT appears to be
a promising strategy, with a theoretically high donor
availability of almost 100%. It also is less time-
consuming than conventional HSCT, which requires
a stringent matching process. Nevertheless, even after
years of application, the high incidence of several crit-
ical complications, including severe graft-versus-host
disease (GVHD), delayed engraftment, severe infec-
tion, and graft failure, still poses a barrier to the wider
application of haploidentical HSCT to the benefit of
more patients.
In recent years, based on surprising advances in
transplantation and immunology, several attempts
have been made to use T cell‒depleted haploidentical
bone marrow (BM) for the prevention of GVHD.
The first ex vivo T cell‒depleted haploidentical
HSCTs using BM were performed in 4 children with
immunodeficiency syndromes more than 20 years
ago; all 4 patients were healthy at 12-15 months after
discharge [5]. Since then, mega-doses of purified stem
cells andT cell‒depleted grafts have been used for hap-
loidentical HSCT, and considerable progress has been
made. Today, with 2 principle protocols—T cell1099
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an encouraging survival rate of 20% has been achieved
in patients with progressive hematologic malignancies
[6]. Using this method, most complications can be pre-
vented or remarkablywell controlled, and in some cases
even cured, due mainly to the application of advanced
medical technologies and novel therapeutic drugs.
According to traditional immunobiological theory,
haploidentical HSCT could be expected to trigger
a more potent graft-versus-tumor (GVT) effect com-
pared with HLA-identical transplants due to the
major histocompatibility complex (MHC) and minor
histocompatibility antigen (mHA) disparities on
donor immune cells and recipient tumor cells, which
might facilitate the repression of tumor relapse.
In fact, a high risk of relapse after haploidentical
T cell‒depleted orTcell‒repleteHSCThas beendocu-
mented in various hematologic malignancies, including
acutemyelogenous leukemia (AML), acute lymphocytic
leukemia (ALL), myelodysplastic syndrome, multiple
myeloma, chronic myelogenous leukemia, and
lymphoma, under both myeloablative and nonmyeloa-
blative (NMA) conditioning regimens, in both children
and adults [7-13]. Studies performed within the past 5
years are summarized in Tables 1 and 2. These reports
infer that relapsed hematologic malignancy after
haploidentical HSCT is still the most common cause
of death, although the specific incidence varies among
reports, possibly due to the heterogeneity in patient
series and diagnostic variations in the different
cohorts. Themechanisms by which high-riskmalignant
cells survive under GVT effects remain elusive,
however.
In our opinion, haploidentical HSCT has merit in
improving survival probability, and haploidentical do-
nors likely would be one of the main stem cell sources.
In this review, we suggest correlating factors and po-
tential mechanisms causing relapse of hematologic
malignancies after haploidentical HSCT, then address
the newly identified indications for relapse, as well as
feasible therapeutic and preventive strategies.POTENTIAL MECHANISMS FOR RELAPSING
HEMATOLOGIC MALIGNANCIES AFTER
HAPLOIDENTICAL HSCT
In ideal haploidenticalHSCT, the initiating condi-
tioning therapy, especially the myeloablative regimen,
eradicates the majority of malignant hematologic cells.
In addition, the posttransplantation GVT effects then
eradicate any residual malignant cells remaining after
conditioning therapy. Thus, in the case of in situ re-
lapse, the residualmalignant cellsmust survive ablation
of the hematopoietic system, which includes malignant
hematologic cells, and also survive the GVT reaction
[38]. According to recent reports, malignant cell resis-
tance to conditioning therapy demonstrated a similarprocess to that involved in drug resistance in chemo-
therapy [39-41], and certain factors might influence
malignancy relapse, including, but not limited to,
the cancerous microenvironment, cancer stem cells,
gene polymorphisms, host ages, GVHD prevention
strategies, disease status at transplantation, and gene
mutations. Here we discuss corresponding factors and
potential immune mechanisms involved in the emer-
gence of relapsing malignancies after haploidentical
HSCT (Figure 1).Pretransplantation: Donor Selection Serves as
an Initial Stage for Preventing Future Relapse
Maternal Tolerance Reduces GVT Potency
Induced by Donor Transplants
Siblings, parents, and offspring are all potential
haploidentical donors. Maternal tolerance and/or im-
munization should make consideration of maternal
transplants a priority. The immune systems of mother
and child are in close contact during pregnancy and
achieve a delicate equilibrium, which might exert an
influence on haploidentical transplantation later in
life.
The maternal immune system, unlike that of the fe-
tus, is mature and usually functional and thus is capable
of being immunized by paternal histocompatibility anti-
gens transmitted from the fetus. Antibodies directed
against paternal HLA antigens [42] and memory type
T lymphocytes directed against paternal major and
minor histocompatibility antigens [43,44] are
frequently found in multiparous women. Under such
circumstances, humoral and cellular immunity against
HLA and mHA in the offspring might mediate
enhanced GVT effects after maternal donor
transplantation. For patients undergoing T cell‒
depleted haploidentical HSCT, even though the
majority of T cells have been removed, the small
population of contaminant memory T cells transferred
with the graft could still spontaneously undergo
unopposed proliferation and play a vital role in
the GVT process by virtue of the absence of
pharmacologic GVHD prophylaxis [33]. Stern et al.
[33] found relapse rates of 22.7% with maternal donors
and 46.5%with paternal donors afterT cell depletion in
vitro excluding the sex effect, supporting the notion that
the use of immunizedmaternal donors is associatedwith
reduced relapsemortalitywith bothTcell‒depleted and
T cell‒replete HSCT. In contrast, for maternal donors
who were not immunized but tolerized during preg-
nancy, low immune reactivity would weaken the recipi-
ent’sGVTeffect, contributing to the higher relapse rate
than seen with immunized maternal donors.
The situation might be different when considering
reciprocal transplantation, in which the mother is the
recipient and the offspring is the donor. It is assumed
Table 1. Recent Studies of T Cell–Replete Haploidentical HSCT
Year, Reference Disease (n) Age, Years, Median (Range) Conditioning Regimen Relapse (Median Follow-Up)
2010 [9] High-risk MDS (36) 34 (10-51) Modified Bu/Cy2 + ATG
(myeloablative)
18.2% in CR, 20.0% in NR (2 years)
2010 [12] Leukemia, multiple
myeloma, MDS (66)
54 (13-70) TBI (or Flu) + Bu + Me-CCNU +
ATG (NMA)
19.1% in high-risk group (9 months)
2010 [14] Leukemia, multiple myeloma,
lymphoma, MDS (86)
44 (21-69) TBI + Cy + Flu (NMA) 58.0% (2 years)
2010 [15] High-risk acute leukemia (14) 32 (8-51) Modified Bu/Cy/ATG
(myeloablative)
29.6% in granulocyte colony-
stimulating factor peripheral
blood stem cells (2 years)
2010 [15] High-risk acute leukemia (109) 25 (3-56) Modified Bu + Cy + ATG
(myeloablative)
34.0% in granulocyte colony-
stimulating factor peripheral
blood stem cells/primed bone
marrow (2 years)
2009 [16] Refractory non-Hodgkin
lymphoma (10)
19 (7-38) TBI + Ara-c + Cy or Bu + Thio +
Cy (myeloablative)
10.0% (60.7 months)
2009 [17] Leukemia, non-Hodgkin
lymphoma (45)
35 (31-39) TBI + Ara-c + Cy + ATG or Bu +
Ara-c + Cy (myeloablative)
24.4% (36 months)
2009 [18] High-risk acute leukemia (33) 23 (7-43) Flu + Ara-c + Cy + ATG +
TBI (NMA)
18.2% (2-7.5 months)
2009 [7] Leukemia (56) TBI (or CCNU + Bu) + Cy +
Ara-C + ATG (myeloablative)
22.0% (207 days)
2009 [19] Leukemia, MDS (58) N/A (3-14) Bu/Cy2 + ATG + Ara-c +
Me-CCNU(myeloablative)
44.6% in high-risk group, 11.3% in
standard-risk group (3 years)
2009 [20] Leukemia (46) 25 (5-54) TBI (or Bu + CCNU) + Ara-c +
Cy + ATG (myeloablative)
23.9% (2 years)
2009 [21] Acute leukemia (250) N/A Ara-c + Bu/Cy + ATG +
semustine(myeloablative)
11.9% and 24.3% for AML and ALL in
standard-risk group; 20.2% and
48.5% for AML and ALL in high-risk
group (3 years)
2008 [22] Leukemia, MDS, lymphoma,
paroxysmal nocturnal
hemoglobinuria (68)
46 (1-71) TBI + Cy + Flu (NMA) 58.0% (2 years)
2008 [23] Acute and chronic
leukemia (42)
N/A (3-14) Ara-c + BuCy + Me-CCNU + ATG
(myeloablative)
37.0% in high-risk group ALL, 0 in AML
and CML (2 years)
2008 [24] Leukemia, lymphoma, and
MDS (30)
30 (16-42) TBI + Flu + Cy + Ara-c
(myeloablative)
20.9% (3 years)
2008 [25] CML (93) 29 (9-54) Bu + Cy + ATG (myeloablative) 3.29% in CML chronic phase, 31.45% in
non–chronic phase (4 years)
2007 [26] Hematologic malignancies (68);
solid tumors (4)
7 (0.5-19) TBI-based or no TBI
(myeloablative or NMA)
0 in CR group, 57.0% in NR
(26 months)
2007 [27] Leukemia, MDS (157) 25 (6-50) Ara-c + Bu/Cy + ATG
(myeloablative)
18.0% (2 years)
2006 [28] Leukemia, MDS (135) 37 (5-50) BuCy2 + ATG (myeloablative) 18.0% (2 years)
2006 [29] Leukemia, MDS (171) 23 (2-56) Me-CCNU + BuCy + Ara-C +
ATG (myeloablative)
12.2% in standard-risk group, 38.9% in
high-risk group (2 years)
HSCT indicates hematopoietic stem cell transplantation; MDS, myelodysplastic syndrome; Bu, busulfan; Cy, cyclophosphamide; ATG, antithymocyte
globulin; CR, complete remission; NR, no remission; TBI, total-body irradiation; Me-CCNU, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea;
Flu, fludarabine; Ara-c, cytarabine; NMA, nonmyeloablative; Thio, thiotepa; N/A, not available; AML, acute myelogenous leukemia; ALL, acute lympho-
cytic leukemia; CML, chronic myelogenous leukemia.
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ble of initiating immunity against noninherited mater-
nal alloantigens. As a result, no decreased risk of
relapse has been reported with the use of offspring as
haploidentical donors. The use of noninherited mater-
nal alloantigen‒mismatched and noninherited pater-
nal alloantigen‒mismatched sibling donors also has
been found to have no statistically significant effect
on the outcome of relapse [33]. Unfortunately, cur-
rently no detailed information is available on donor
humoral and cellular immune reactivity against mis-
matched HLA on recipient cells before transplanta-
tion, and we cannot yet exclude the possibility that
some family members might be immunized by differ-
ent HLA molecules expressed in patients through as-
yet unclarified pathways. In any case, when assessingthe maternal factors recorded during pregnancy,
stem cell donor alloimmune status should be deter-
mined when selecting a haploidentical donor from
among family members or other relatives, to achieve
a potent GVT effect after haploidentical HSCT.
HLAGenetic and Epigenetic Variations Affect the
GVT Reaction
The frequency of HLA-mismatched loci in haploi-
dentical donors ranges from 1 to 5 in 10/10 alleles.
HLA mismatches can involve different numbers of
mismatched locus sites and different combinations of
HLA mismatches. HLA-mismatched donor‒recipient
combinations have widely varying effects on the risk of
relapse post-HSCT, particularly with respect to HLA-
DPB1 and HLA-Cw disparities [45-47]. To date, no
Table 2. Recent Studies of T Cell‒Depleted Haploidentical HSCT
Year, Reference Disease (n) Age, Years, Median (Range) Conditioning Regimen Relapse Rate (Median Follow-Up)
2010 [30] ALL (102) 8.7 (0.64-16) TBI-based or not (unknown) 36.0% in CR (5 years)
2010 [31] Leukemia, MDS,
lymphoma (28)
36 (6-56) Melphalan + Thio + Flu +
ATG (NMA)
44.0% in advance, 0 in CR (72 days)
2010 [32] Leukemia, lymphoma
(28)
45 (19-65) Flu (cladribine) + Thio +
melphalan + OKT-3 (NMA)
28.6% (748 days)
2008 [33] Leukemia (118) 18 (2-52) TBI + Thio + Flu (or Cy) +
ATG (myeloablative)
22.7% in mother donor, 46.5% in
father donor (3.4 years)
2008 [34] Leukemia (266) 31 (16-66) TBI-based regimen
(myeloablative)
AML: 16% in CR1, 23% in CR2, 32% in
advance; ALL: 26% in CR1, 27% in
CR2, 49% in advance (2 years)
2007 [35] AML (112) N/A TBI + Flu (methotrexate) +
ATG (myeloablative)
25.0% (5.07 years)
2007 [36] Hematologic malignancies or
advanced myeloproliferative
disorder (49)
48 (17-66) Alemtuzumab + Flu + Cy
(NMA)
49.0% (unknown)
2006 [37] ALL, AML (34) 11 (1-16) TBI + Cy-based (myeloablative) 13.0 in CR, 100.0 in NR (62 months)
HSCT indicates hematopoietic stem cell transplantation; ALL, acute lymphocytic leukemia; TBI, total-body irradiation; CR, complete remission; MDS,
myelodysplastic syndrome; Thio, thiotepa; Flu, fludarabine; ATG, antithymocyte globulin; NMA, nonmyeloablative; Cy, cyclophosphamide; AML, acute
myelogenous leukemia; N/A, not available.
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among various mismatched loci.
Particular HLA antigens have varying immunoge-
nicity in recipients. One or two amino acids might af-
fect several determinants of alloreactivity; for example,
Ser9C-Tyr9C and Phe99C-Tyr99C at variant posi-
tions are responsible for a decreased risk of relapse
[48]. For a pregnant woman, alloantibodies are fre-
quently induced by fetus-derived HLA-A2 or HLA-
B5 mismatches, whereas a fetus bearing HLA-A30,
-A31, or -A33 orHLA-A28 induced alloantibodies sig-
nificantly less often than a fetus bearing other HLA
class I mismatches [49]. Correspondingly, the donor
immune system, recognizing different haploidentical
recipient HLA antigens with different immunogenic-
ity, might trigger theGVT effect andGVHD at differ-
ent levels, and the GVT effect may correlate with the
incidence of relapse posttransplantation. Moreover,
the expression profiles of mismatched HLA and adhe-
sion molecules on malignant cells and tentative malig-
nant stem cells might be as varied as on normalFigure 1. Correlating factors on relapsing hematologic malignancies af-
ter haploidentical HSCT.hematopoietic cells and daughter cells, affecting
GVT intensity in HLA-mismatched recipients [48].
These findings suggest that clarifying the HLA locus
disparity and adhesion molecule expression profiles
in haploidentical HSCT settings would be very helpful
and could lead to improvements in therapy.
Killer Immunoglobulin-Like Receptors Impede
Natural Killer Cell‒Mediated Cytotoxicity
Natural killer (NK) cells are the first lymphoid cells
to recover, appearing as early as 2-3 weeks posttrans-
plantation by rapid differentiation from engrafted
CD341 cells.They express activating and inhibitory re-
ceptors, termed killer immunoglobulin-like receptors
(KIRs), which stimulate or inhibitNK cell cytotoxicity,
respectively. KIRs are characterized by 2 (KIR2D) or 3
(KIR3D) extracellular immunoglobulin domains spe-
cifically recognizing MHC class I molecules as their li-
gands [14,50]. In an allogeneic transplant recipient
undergoing haploidentical HSCT with selected
CD341 cell or T cell depletion, alloreactive NK cells
are characterized by the expression of KIRs that are
not engaged by any of the HLA class I alleles
expressed by the recipient—namely mismatched KIR
ligands, which recognize and eradicate residual
malignant cells through antibody-dependent cell-me-
diated cytotoxicity, complement-dependent cell-medi-
ated cytotoxicity, Fas-dependent killing and perforin
degranulation, and other methods. In the best case, T
cells andNK cells would to some extent atone for their
tumoricidal capacities by virtue of their differentially
cytotoxic mechanisms.
There is considerable evidence indicating that
alloreactive NK cells developing from haploidentical
HSCT represent a group of the most potent effector
cells that can successfully treat high-risk leukemia
and reduce recurrence after both T cell‒depleted and
T cell‒replete transplants [51-53]. In patients with
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HSCT, Ruggeri et al. [54] found lower relapse rates
in recipients of KIR ligand-matched transplants com-
pared with recipients of mismatched transplants (75%
vs 0). Leung et al. [55] reported a reduced rate of re-
lapse in patients with ALL. Recently, Symons et al.
[14] reported that KIR haplotype AA recipients of
BM from KIR Bx donors had a lower relapse rate in
T cell‒replete haploidentical HSCT with NMA con-
ditioning [14]. Other clinical trials using adoptive
transfer of allogeneic NK cells in combination with
haploidentical transplantation have shown lower re-
lapse rates compared with matched NK ligands, while
donor NK cells can compensate for the paucity of
T cell–specific alloreactivity depleted in the graft
[51,56,57].
The characteristics of KIR and its ligands are com-
plicated. The application of alloreactive NK cells to
treat haploidentical HSCT, which potentiates the at-
tenuation of NK cell‒mediated cytotoxicity associated
with the high risk of relapse after haploidentical
HSCT is an area warranting further investigation.Peritransplantation: Graft Component
Variability as a Precarious Factor that Hinders
the GVT Effect
The HSCT allograft consists mainly of CD341
hematopoietic stem cells and alloreactive immune cells
including T cells, B cells, andNK cells. Of these, allor-
eactive T cells are the most important effector cells in
eliciting both GVHD and the GVT reaction, activated
by the host’s dendritic cells (DCs) through the presen-
tation of mHA, MHC, or tumor-associated antigen.
After activation, the T cells release cytokines, includ-
ing interferon-g and granulocyte macrophage
colony-stimulating factor, resulting in a vicious cycle
known as a ‘‘cytokine storm,’’ which leads to GVHD
and the GVT reaction. NK cells (as described above)
and B cells are considered to serve as effector cells
with significant roles, but acting through different
mechanisms [58].
The major alloreactive T cells in allografts are de-
pleted in somehaploidenticalHSCTs.TheGVTeffect
could be abrogated after T cell‒depleted HSCT. This
is considered a major cause of the high risk of relapse
[59-61]. Despite this, previous studies have shown
that the residual T cells in the allograft are sufficiently
potent to trigger a GVT effect. Recently, several
unmanipulated haploidentical blood and marrow
transplantations elicited a potent GVT effect with no
influence on GVHD severity [11,21]. Under such
transplantation conditions, T cell subtype distribution
might have some effect on relapse. The CD4/CD8
ratio is a conventional measure of immune function
and response because CD41 T cells are associated
with helper/inducer function, whereas CD81 T cellsare associated with cytotoxic/suppressor activity [62].
Thus, the CD4/CD8 ratio in grafts can affect immune
function and theGVTeffect. Clinical experience shows
that a lowCD4/CD8 ratio is always associated with low
risk of relapse and vice versa [62,63]. The number of
CD31 cells in the allograft is likely another important
factor in determining the risk of relapse. It should be
noted that these data were collected from a small
number of patients; larger-scale clinical trials are
needed to verify and clarify our results.
B cells are one of the main cell types involved in
humoral immune responses. They act as antigen-
presenting cells, create antibodies against foreign anti-
gens, and develop into memory B cells or plasma cells.
Few previous studies have examined whether anti-
bodies produced by donor B cells also might contrib-
ute to tumor immunity after allogeneic HSCT
(allo-HSCT). Interestingly, recent studies suggest
that B cells also likely play an important role in the
GVT effect [38,58]. In addition, the roles of the
number of CD341 cells, as well as other cell types
transfused within grafts for haploidentical HSCT,
merit further investigation. The reduced GVT effect
in a variety of graft conditions may be attributed to
the paucity of effector T cells, delayed immune
reconstitution, incompletely activated B cells in the
allograft due to lack of T cells, and impaired DC
function due to the shortage of cytokines produced
by effector T cells.Posttransplantation: Intensive
Immunosuppression Is a Double-Edged Sword
An intensive immunosuppressive regimen should
be administered to patients undergoing haploidentical
HSCT, especially those with T cell‒replete transplan-
tation, both during the conditioning regimen and after
transplantation to prevent severe GVHD and graft
failure. Traditional immunosuppressive agents include
antithymocyte globulin, cyclosporine, methotrexate,
glucocorticoids, and mycophenolate mofetil. Most of
these agents inhibit the functions of various immune
cells, including the immune cells initiating GVHD
and the GVT effect, as well as other immune cells ab-
rogating GVHD [64-66]. Accordingly, intensive use of
immunosuppressive agents might weaken the immune
function of donor cells (the main effector cells of the
GVT reaction), resulting in primary disease relapse.
There are plenty of clinical examples in which the
administration of intensive immunosuppressive
agents caused disease relapse [67,68]. After
withdrawal of immunosuppressive agents, some
relapsed patients achieved complete remission (CR)
with no any further treatment [69]. Donor lymphocyte
infusion (DLI) is another example of weak immune cell
function contributing to disease recurrence. After DLI
treatment, some patients can achieve CR [70].
1104 Biol Blood Marrow Transplant 17:1099-1111, 2011Y.-X. Hu et al.Lymphocytes applied in DLI are isolated from donor
blood, which is free of contact with immunosuppres-
sive agents and thus is functionally competent to exert
GVT effects through multiple pathways.What immu-
nosuppressive agents to use, how many, and how long
therapy should be applied to achieve equilibrium by
reducing GVHD while maintaining the GVT effect
to prevent relapse of primary malignancies remains
a difficult problem.A Potentially Neglected Factor: Loss of
Mismatched HLA Haplotype
The HLA superlocus contains a large number of
genes related to immune system function in humans.
This group of genes resides on chromosome 6 and en-
codes cell-surface antigen-presenting proteins and
many other genes. Genomic or phenotypic alterations
of HLA and the antigen-presenting machinery are fre-
quently seen in patients with solid tumors [71,72]. Loss
of HLA class I surface antigens also has been described
in patients with melanoma after a partial response to
cellular immunotherapy [73]. In essence, a major
contributor to the appearance ofMHC class I-negative
tumor clones is T cell immune selection. Malignant
cells with total MHC class I loss are susceptible to
NK cell lysis via repression of surface inhibitory
receptors. However, partial loss of HLA class I anti-
gens facilitates the escape of tumor cells from cyto-
toxic T lymphocyte (CTL)- and NK-mediated
immune pressures. Further analysis has shown that
a loss of HLA haplotype is associated with loss ofFigure 2. Schematic representation of loss of mismatched haplotype (A) and l
HSCT leading to relapse. Patients without mutations in malignant cells maintaheterozygosity, including 1 copy of chromosome 6 or
a DNA fragment containing HLA-A, HLA-B, and
HLA-C genes.
In haploidentical HSCT, alloreactive T cell re-
sponses could be directed against epitopes on HLA
molecules or against peptide‒HLA complexes ex-
pressed onmalignant cells viaGVTeffects. This would
exert immunologic pressure on malignant cells at the
same time. For relapsing malignancies after HSCT or
reduced-intensity conditioning transplantation, DLI
is usually applied repeatedly, whichmight cause poten-
tial immune selection and the loss of certain HLA hap-
lotypes, leading to impaired specific GVT effects.
Recently, Vago et al. [74] reported mutant leukemic
cells in 5 of 17 patients with leukemia relapse after hap-
loidentical transplantation and infusion of donor T
cells, in which the HLA haplotype that differed from
the donor’s haplotype had been lost because of ac-
quired uniparental disomy of chromosome 6p. A recent
independent report found that 2 out of 3 patients who
relapsed after HLA-haploidentical HSCT demon-
strated loss of HLA alleles in leukemic cells at relapse
and a copy number‒neutral loss of heterozygosity;
that is, they acquired uniparental disomy on the short
arm of chromosome 6, resulting in the total loss of
the mismatched HLA haplotype [75]. Due to this loss
ofmismatchedHLAhaplotype, bothT cells andB cells
targeting the mismatched HLA molecules failed to
eradicate the residual tumor cells, leading to malig-
nancy relapse (Figure 2). These reports revealed a pre-
viously neglected phenomenon in the process of
haploidentical HSCT relapse, in which leukemic cellsoss of heterozygosity (B) in hematologic malignancies after haploidentical
in complete remission because of a potent GVTeffect (C).
Biol Blood Marrow Transplant 17:1099-1111, 2011 1105Relapsing Malignancies after Haploidentical HSCToccasionally escape from immune surveillance through
the loss ofmismatchedHLA haplotypes by uniparental
disomy, under the influence of immunologic pressures.
The mechanism underlying the acquired unipa-
rental disomy of chromosome 6p after haploidentical
HSCT remains a mystery. It is also not known
whether there are any alterations in gene expression
or gene mutants of mHAs after HLA-identical or
HLA-mismatched HSCT that unltimately result in
hematologic malignancy relapse. To fully understand
these points, note should be taken of HLA haplotype
expression profiles, which have been previously
neglected.THERAPEUTIC AND PREVENTIVE
STRATEGIES FOR RELAPSING
HEMATOLOGIC MALIGNANCIES
Because relapsing malignancy is a nascent branch
of HSCT treatment, the prognosis of relapsing hema-
tologic malignancies after allo-HSCT is extremely
limited, although various treatments have been applied
in the clinic. However, as proof of principle, these
strategies should be differentially adopted to cope
with specific relapsing factors andmechanisms. Unfor-
tunately, currently there is no effective detection sys-
tem for distinguishing corresponding factors and
mechanisms individually. Conventionally, the first in-
tervention for relapsing hematologic malignancy with
a low tumor burden is to enhance the GVT reaction,
because controlling the malignancy depends almost
entirely on the GVT effect. In patients with a high tu-
mor burden or who show no improvement after theFigure 3. Summary of current clinical interventifirst intervention, reinduction of chemotherapy with
or without enhancement of the GVT effect to eradi-
cate relapsing malignancies should be considered
(Figure 3). However, some generally acknowledged
criteria should be established to identify the scale of
the tumor burden. To treat these patients, a second
allo-HSCT may be an endpoint choice; in addition,
novel technologies and other pipeline drugs with dif-
ferent mechanisms may offer alternatives in the near
future.Enhancement of the GVT Effect
Donor immune cells are always at lower levels of
immunity in recipients of haploidentical HSCT com-
pared with recipients of other types of HSCT, proba-
bly due to the prolonged and intense treatment with
immunosuppressive agents, delayed immune reconsti-
tution, andT cell depletion in the allograft. Thus, hap-
loidentical HSCT recipients are likely to benefit more
from strategies that enhance recipient immunity.More
investigations are needed to validate this finding.
Withdrawal of Immunosuppressive Agents
Withdrawal of immunosuppressive agents (WIA)
is generally the first option in relapsing hematologic
malignancies with either low or high tumor burden af-
ter allo-HSCT. WIA, especially for cyclosporine as
immunotherapy for leukemia relapse, showed some ef-
fects in HLA-matched and HLA-mismatched cases,
including haploidentical HSCT [76,77], but detailed
response rates were not analyzed. In contrast, other
independent investigations showed that WIA had
a limited effect on relapse treatment [78], whichons after relapse post-haploidentical HSCT.
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suitable for patients in relapse without GVHD mani-
festations. In patients in relapse with complications
of GVHD, WIA might not be an effective choice.
For patients who relapse or show no improvement af-
terWIA, alternative strategies to improveGVT effects
should be considered. Notably, for these patients, the
presence of GVHD should be carefully considered be-
fore opting for WIA.Donor Immune Cell Infusion
Donor immune cell infusion is a developing tech-
nique aimed at eradicating relapsing tumor cells.
DLI was first identified as an effective therapeutic
and preventive strategy for relapsing hematologic ma-
lignancies after allo-HSCT [79]. Immunosuppressive
agents should be administered during DLI to prevent
GVHD and pancytopenia, which greatly reduces the
GVT effect. Clinical trials on the use of modified
DLI, such as adaptive transfer of donor-derived leuke-
mic reactive T cells and mHA-specific CTLs without
administration of immunosuppressive agents, aiming
to achieve the strongest GVT effect with the least
side effects, are currently under way [80]. Cell fate con-
trol gene therapy, another type of modified DLI, also
has been proposed [81]. ‘‘Suicide’’ gene therapy target-
ing donor T cells can provide a molecular switch to
control in vivo survival efficacy, which can enable max-
imal GVT responses to achieve the greatest attainable
antitumor effects.
Patients in relapse after haploidentical HSCT also
would benefit from other modified DLI modalities.
Mismatched HLA loci are thought to be good GVT
targets. Currently, various HLA epitopic peptides, as
well as dissociated hematopoietic-specific antigens, in-
cluding CD45, CD3, and CD20, are available, allow-
ing the development of novel immunotherapeutic
trials. Based on recent reports, haploidentical donor
T cells could be cocultured with donor DCs engi-
neered to present the recipient HLA locus and conju-
gated with a peptide derived from a recipient
hematopoietic antigen. Such HLA locus/hematopoi-
etic antigen pentamer-reactive cytotoxic CD81T cells
could be readily obtained from haploidentical donors.
These allorestricted T cells would provide GVT ef-
fects in the absence of GVHD even without the use
of immunosuppressive agents. Abrahamsen et al. [82]
obtained highly specific allogeneic T cells targeting
B cell leukemia with high CD20 specificity using an
HLA-A*0201/CD20p pentamer in vitro. Through
this approach, potent efficacy has been achieved in
haploidentical adoptive CTL therapy for Epstein-
Barr virus‒associated lymphoma after HSCT [83], as
well as in vaccination for patients with metastatic mel-
anoma using a gp100-derived epitopic peptide
restricted to HLA-A*2402 [84]. Based on theseachievements, immunotherapeutic strategies targeting
the mismatched HLA locus of relapsing hematologic
malignancies after haploidentical HSCT could have
wide applicability in the clinic, especially taking into
account their synergistic effects in combination with
standard therapeutic modalities.
In addition to T cell‒based strategies, NK cells as
innate immune cells with non-HLA restricted cytotox-
icity are also an attractive population. In haploidentical
HSCT settings, differentiation of KIR1 alloreactive
NK cells from hematopoietic stem cell precursors
may require 6-8 weeks, and thus their antileukemia ef-
fect may occur only after this time period. In cases of
high residual tumor burden and/or rapidly proliferat-
ing leukemia blasts, especially after T cell–depleted
haploidentical HSCT, as mentioned earlier, this delay
may be a major limitation, leading to leukemic relapse.
With the aim of reducing this risk, mature alloreactive
NK cells isolated from the haploidentical donor could
be infused shortly after HSCT. These mature donor
NK cells could be properly mobilized with specifically
activating cytokines, such as interleukin-15, which is
believed to cause a strong GVT reaction but no
GVHD. Ruggeri et al. [85] suggested that the alloreac-
tivity of donor-versus-recipient NK cells in human
transplants could eliminate both leukemia relapse
and graft rejection, and protect patients against
GVHD.
For other immune cell subpopulations, such as gd
T cells and NK T cells, which have demonstrated tu-
moricidal effects in in vitro and in vivo studies [86-88],
their effects on treatment of relapsing malignancies
after HSCT requires further investigation.
In general, to achieve synergistic effects in combi-
nation with standard therapeutic modalities, we would
incorporate the newly available modified infusion
technologies, sensitizing relapsing hematologic malig-
nancies to donor immune cell infusion. Donor im-
mune cell infusion is likely to play an increasingly
important role in treating and preventing relapsing he-
matologic malignancies after haploidentical HSCT in
the future, due to the decreased immunity as well as the
limted availability and feasibility of obtaining such
cells from haploidentical donors, unlike from unre-
lated donors.Targeted Therapy
Targeted therapy is often combined with donor im-
mune cell infusion or reinduction chemotherapy in spe-
cific diseases. Currently, targeted drugs for treating
hematologic malignancy include monoclonal anti-
bodies and tyrosine kinase inhibitors (TKIs). Monoclo-
nal antibodies contain tumor antigen‒specific agents
(eg, anti-CD20, anti-CD33, anti-CD52), which might
enhance the GVT effect through complement-
dependent cell-mediated cytotoxicity as well as
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anti-CTLA4. CTLA4 is induced on T cells on activa-
tion and is an important mediator of peripheral
self-tolerance and tolerance to tumor antigens. Anti-
CTLA4 (ipilimumab) is a fully human IgG1 monoclo-
nal antibody that antagonizes CTLA4, thus leading to
persistent T cell activation, and has recently been li-
censed as a drug for GVT enhancement. Bashey et al.
[89] demonstrated that anti-CTLA4 was a potential
therapy for relapsing hematologic malignancies after
allo-HSCTwithout causingGVHDandgraft rejection.
More clinical trials are needed to clarify this finding.
Although TKIs have not been found to enhance
donor cell immunity, they are the most effective
agents for eradicating Ph1 leukemia including chronic
myelogenous leukemia and Ph1 ALL. Because of mu-
tations in the BCR/ABL gene, some TKIs are ineffec-
tive. New generations of TKIs have different kinetics
of tyrosine inhibition. Some patients with mutations
in the BCR/ABL gene relapse after allo-HSCT but
achieve CR after TKI treatment. Recently developed
FLT3-TKIs target the high levels of FLT3 expressed
in AML blasts (70%-100%) and ALL blasts [90].
The use of novel monoclonal antibodies against
mismatched MHC antigens specifically expressed on
hematopoietic cells is another potentially targeted fu-
ture therapy for relapse after haploidentical HSCT.
The use of a bispecific antibody (diabody) targeting 2
antigens is another promising strategy for tumor ther-
apy [91]; this could be designed to target both mis-
matched MHC and leukemic antigens to achieve
a perfect antileukemia effect without causing GVHD
in patients who relapse after haploidentical HSCT.
Epigenetic Modifiers
Epigenetic modifiers are often combined with
other immunity-enhancing strategies. The hypome-
thylating agent 5-azacytidine (Aza) has been shown
to be an effective epigenetic modifier for GVT en-
hancement. Aza restores the expression of GVT-
targeted antigens including mismatched mHA, HLA,
and tumor-associated antigens in leukemic cells, effec-
tively facilitating restoration of the ability of donor im-
mune cells to eradicatemalignant cells. Dubovsky et al.
[92] reported that treating chronic lymphocytic leuke-
mia (CLL) cells with Aza unleashed target antigen ex-
pression. These investigators also found that
a combination of 2 epigenetic modifiers, Aza and the
histone deacetylase inhibitor LAQ824, effectively re-
stored the immunogenicity of CLL cell lines and pri-
mary cells from patients with CLL. Indeed, such
a combination induces the expression of novel and
highly antigenic cancer/testis antigens and costimula-
tory molecules [92]. These changes further facilitate
the formation of robust supramolecular activation
complexes between malignant cells and responder Tcells, leading to intracellular signaling, lytic granule
mobilization, and polarization of functional and
relevant T cell responses. The cascades of T cell‒
activating events triggered by malignant cells indicate
that combined epigenetic modifier treatment is a po-
tential immunotherapeutic strategy for some relapsed
patients after allo-HSCT [92]. Regarding haploident-
ical HSCT, epigenetic modifiers can restore mis-
matched HLA-locus expression in leukemic cells,
thus a robust GVT effect could also be initiated.
Reinduction Chemotherapy with or without an
Enhanced GVT Effect
Reinduction chemotherapy in specific regimens
without initial administration is effective for some che-
mosensitive diseases, although the long-term efficacy
is far lower than expected. According to some reports,
intensified chemotherapy should be performed to
achieve CR or cytoreduction on the premise of being
tolerated [93,94]. GVT-enhancing strategies are often
combined to eradicate tumor cells resistant to reinduc-
tion chemotherapy. Even if patients achieve CR again
after reinduction chemotherapy with or without an en-
hanced GVT effect, they are vulnerable to sudden re-
lapse in the absence of further management, whereas
the subsequent treatment of patients achieving CR or
no remission (NR) remains a challenging issue. De-
spite this dilemma, reinduction intervention provides
a new opportunity for a second allo-HSCT, which
would provide new hope for such special populations.
Second Allo-HSCT
Whether or not patients with relapsing hemato-
logic malignancy benefit from a second allo-HSCT re-
mains controversial. Today only a minority of patients
undergoing second allo-HSCT have been reported to
have high morbidity and mortality. Outcome is associ-
ated with such factors as recipient age, underlying dis-
ease, disease status, and second donor type. Kurosawa
et al. [95] reported significantly higher 1-year overall
survival after second allo-HSCT compared with other
interventions (58% vs 14%). Second allo-HSCT in-
volving different donors would reconstitute immunity
and induce GVT effects against different antigens. In
cases involving loss of mismatched HLA in relapsing
malignant cells after haploidentical HSCT, second
allo-HSCT using the same donor would be ineffective.
NMAHSCT has been demonstrated to reduce nonre-
lapse mortality but to increase relapse rate; however,
whether this technique can benefit patients cannot be
determined without more data from clinical trials.
Regarding other preventive strategies, conducting
regular follow-up checks to detect donor immune sta-
tus in recipient, monitoring minimal residual disease,
and adjusting the quantity of immunosuppressive
agents are most important. Some recent clinical trials
Figure 4. The proposed therapeutic regimens with the advent of a system for detecting factors and mechanisms predictive of future relapse.
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rism of donor and recipient is an important predictor
of relapse post-HSCT in patients with hematologic
malignancy [96]. The role of chimerism monitoring is
elusive. Donor selection and allograft components are
other important factors, although consistentworldwide
standards are needed. Progress in the use of allografts
with T cell subset depletion, selective allodepletion,
or T cell anergization would be equally beneficial.CONCLUSION
Haploidentical HSCT is a potentially curative ther-
apy for hematologic malignancies. As novel medical
technologies and drugs emerge, severeGVHDand graft
failure and infection can be prevented or controlled
while malignancy relapse remains unresolved, causing
high morbidity and mortality. In this review, we have
summarized tentative immune factors and mechanisms
associated with a high risk of relapse after haploidentical
HSCTandhavediscussedpertinent strategies toprevent
or treat relapsing hematologic malignancies. Neverthe-
less, how to reduce the relapse rate remains a difficult
question for both hematologists and researchers.
To achieve better treatment for haploidentical re-
cipients, several crucial topics require further clarifica-
tion. More clinical trials on donor selection should be
considered, as well as the establishment of worldwide
standards for haploidentical donor selection. Large-
scale clinical trials and underlying research concerning
graft components, such as the distribution ofT cell sub-
types, dose of CD341 hematopoietic stem cells, CD4/
CD8 ratio, and numbers of NK and B cells, should be
performed. Specific immunosuppressive agents shouldbe developed to specifically inhibit T cell subsets caus-
ing GVHD while ideally improving the GVT effect.
Novel approaches for evaluating immune cell function
should be developed to allow clinicians to readily adjust
the optimal dose of immunosuppressive agents in
a timely manner according to the recipient’s status, as
well as the donor immune status. Novel factors and
mechanisms affecting the high risk of relapse require
further elucidation at both the cellular and molecular
levels, as well as detecting methods affecting these fac-
tors and mechanisms, which would undoubtedly con-
tribute to the prevention and treatment of individual
primarymalignancies. Proposed future therapeutic reg-
imens are illustrated in Figure 4. Finally, new strategies
targeting mismatched hematopoietic MHC antigens,
such as monoclonal antibodies and diabodies to eradi-
cate malignancies, should be developed.ACKNOWLEDGMENTS
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